Xeptagen SpA Overview
Company Headquarters: Venice, Italy
Founded: 2001
Company Working: Xeptagen SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early-stage cancer and the proprietary platform technology Combinatorial Proteomic, Xeptagen SpA has discovered predictive, prognostic, and early-response tumor markers that lead to earlier and much more accurate detection of developing carcinomas.
Strategy
Xeptagen SpA focuses on improving product outcomes more efficiently and helping healthcare providers, researchers, and life science companies to achieve their goals. The company also focuses on expanding its footprints in emerging markets and create innovative tools that improve the clinical management of patients.
